IMCR — Immunocore Holdings plc

—

Nasdaq · Health Care · Biotechnology · CIK 1671927 ·

Last close

$31.95

Market Cap

$1.63B

52W High

$34.01

52W Low

$27.56

ADV30

600,719

Next earnings

2026-08-06

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

Period	Revenues	GrossProfit	OpIncome	NetIncome	Assets	Cash	Liabilities
Mar 2026	106,677,000	106,243,000	7,280,000	12,971,000	1,072,095,000	452,675,000	678,422,000
Dec 2025	104,478,000	101,775,000	-19,691,000	-30,060,000	1,067,269,000	467,709,000	686,236,000
Sep 2025	103,693,000	103,180,000	-7,171,000	-177,000	1,102,500,000	498,413,000	705,936,000
Jun 2025	97,964,000	96,924,000	-14,875,000	-10,300,000	1,082,387,000	487,933,000	693,906,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF

$-10,712,000

Investing CF

$-16,340,000

Financing CF

$12,371,000

CapEx

$-4,340,000

Dividends Paid

—

Buybacks

—

EPS Diluted TTM

$-0.70

As of

2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings

$-831,275,000

Inventory

$6,742,000

Receivables

$101,121,000

ST Investments

$396,444,000

EBIT TTM

$-6,425,000

Pretax Income TTM

$-19,100,000

Interest Exp TTM

$12,675,000

Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue

$412,812,000

EBITDA

$-11,369,000

Free Cash Flow

$58,577,376

Enterprise Value

$1,273,420,160

Total Cash

$844,896,000

Total Debt

$435,683,008

Shares Out

50,865,574

Trailing EPS

$-0.56

Book Value

$7.75

ROE

-7.1%

ROA

-0.9%

Div Yield

—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY end	Revenues	OpIncome	NetIncome	Assets	Liabilities	Equity	OCF
Dec 2025	400,016,000	-45,353,000	-35,514,000	1,067,269,000	686,236,000	—	-10,712,000
Dec 2024	310,202,000	-70,461,000	-51,087,000	1,009,506,000	648,790,000	—	26,061,000
Dec 2023	249,428,000	-59,649,000	-55,287,000	597,001,000	228,158,000	—	2,940,000
Dec 2022	174,361,000	-51,708,000	-52,543,000	526,762,000	187,859,000	—	-49,209,000

TTM Snapshot

Revenues TTM

$145,098,000

NetIncome TTM

$9,642,000

OpCashFlow TTM

Assets (Latest)

$1,009,506,000

Forward EPS

$-0.62

Peers — same industry

Ticker	Name	Market Cap	Last	Daily %
VIR	Vir Biotechnology, Inc.	$1.68B	$9.96	—
MAZE	Maze Therapeutics, Inc.	$1.69B	$30.57	—
NVAX	NOVAVAX INC	$1.53B	$9.33	—
COAG	Hemab Therapeutics Holdings, Inc.	$1.78B	$38.03	—
TSHA	Taysha Gene Therapies, Inc.	$1.82B	$6.34	—

News headlines (Yahoo Finance, 1h cache)

Is Immunocore Holdings (IMCR) Undervalued After Its Recent Share Price Rebound?

2026-07-09 15:11 · Yahoo

AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study

2026-07-07 14:10 · Yahoo

TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia

2026-07-07 12:58 · Yahoo

Reasons Why Investors Should Consider Betting on Neurocrine Stock

2026-07-06 14:45 · Yahoo

UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal

2026-07-03 12:55 · Yahoo

Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT

2026-07-02 14:42 · Yahoo

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data

2026-07-02 13:34 · Yahoo

PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare

2026-07-02 13:32 · Yahoo

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

2026-07-01 14:41 · Yahoo

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why